Previous 10 | Next 10 |
– Phase 1 Study will Assess First-in-Class Switch-control ULK Kinase Inhibitor Designed to Inhibit Autophagy as a Single Agent and in Combination with a MEK Inhibitor – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical...
Deciphera Pharmaceuticals ([[DCPH]] -0.5%) posts data from the company's late-stage INVICTUS study of QINLOCK in patients with advanced gastrointestinal stromal tumor ((GIST)), as well as preliminary results from its Phase 1b/2 study of rebastinib in combination with paclitaxel in patien...
– Exploratory Analysis of the INVICTUS Phase 3 Study Showed QINLOCK Dose Escalation After Disease Progression Provided Substantial Clinical Benefit in Advanced GIST – – Rebastinib in Combination with Paclitaxel in a Phase 1b/2 Study Demonstrate...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) are trading close to a 52-week low of $33.55 -- pretty far from the $57.89 they commanded last year at this time. The company, which went public with an IPO in 2017, got a big bump late in 2019 on positive phase 3 trials for its...
Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2021 Earnings Conference Call May 4, 2021 16:30 ET Company Participants Jen Robinson - Vice President, Investor Relations Steven Hoerter - President & Chief Executive Officer Daniel Martin - Chief Commercial Officer Matthew Sherman - Chief Medical...
Image source: The Motley Fool. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q1 2021 Earnings Call May 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2021 Earnings Call...
Deciphera Pharmaceuticals (DCPH): Q1 GAAP EPS of -$1.06 beats by $0.01.Revenue of $25.2M, beats by $2.15M.Press Release For further details see: Deciphera Pharmaceuticals EPS beats by $0.01, beats on revenue
- First Quarter 2021 QINLOCK® Net Product Revenue of $20.0 Million; QINLOCK Approved in China and Hong Kong for Fourth-line GIST - - Top-line Results from INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line GIST Expected in the Fourth Quarter of 2021; Plans to ...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
Deciphera Pharmaceuticals Inc. Website:
– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...